132 related articles for article (PubMed ID: 3132591)
1. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Case DC; Anderson J; Ervin TJ; Gottlieb A
Med Pediatr Oncol; 1988; 16(3):182-6. PubMed ID: 3132591
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552.
Case DC; Anderson J; Ervin TJ; Gottlieb A
Hematol Oncol; 1991; 9(4-5):189-96. PubMed ID: 1743622
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
Case DC; Santarelli MT; Carey RW; Anderson J; Gottlieb A
Med Pediatr Oncol; 1992; 20(4):325-9. PubMed ID: 1608355
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and Mesna in advanced malignancies.
Li GC; Brock N; Li JQ; Guan ZZ; He YJ
Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
[No Abstract] [Full Text] [Related]
7. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
[TBL] [Abstract][Full Text] [Related]
8. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Falkson G; Van Dyk JJ; Stapelberg R; Falkson HC
Cancer Chemother Pharmacol; 1982; 9(2):81-4. PubMed ID: 6816479
[TBL] [Abstract][Full Text] [Related]
9. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
10. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Czownicki Z; Utracka-Hutka B
Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
[No Abstract] [Full Text] [Related]
12. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
Hannigan EV; Dinh TV; Doherty MG
Gynecol Oncol; 1991 Nov; 43(2):123-8. PubMed ID: 1743553
[TBL] [Abstract][Full Text] [Related]
14. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Marti C; Steiner R; Viollier AF
Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
[TBL] [Abstract][Full Text] [Related]
15. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Antman KH; Ryan L; Elias A; Sherman D; Grier HE
J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
[TBL] [Abstract][Full Text] [Related]
16. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
17. Clinical overview of mesna.
Burkert H
Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
[TBL] [Abstract][Full Text] [Related]
18. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide with mesna uroprotection in the management of lung cancer.
Holoye PY; Glisson BS; Lee JS; Dhingra HM; Murphy WK; Umsawasdi T; Levy JK; Jeffries D; Raber MN; Hong WK
Am J Clin Oncol; 1990 Apr; 13(2):148-55. PubMed ID: 2156418
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Walters RS; Holmes FA; Valero V; Esparza-Guerra L; Hortobagyi GN
Am J Clin Oncol; 1998 Aug; 21(4):413-5. PubMed ID: 9708645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
